Forte Biosciences, Inc. (NASDAQ: FBRX) is a clinical‐stage biotechnology company focused on developing novel, microbiome-inspired therapeutics for dermatological and inflammatory skin conditions. The company’s research and development efforts center on the use of proprietary live biotherapeutic formulations designed to modulate the skin microbiome, offering an alternative to traditional small‐molecule and biologic therapies. Forte’s lead candidate, FB-101, is being evaluated in Phase 2 trials for mild-to-moderate acne, while its pipeline also includes FB-401 for atopic dermatitis and FB-102 for vitiligo.
Since its inception, Forte has leveraged advances in microbiome science to identify and cultivate specific bacterial strains with potential to restore skin health. The company applies a precision medicine approach, integrating data from genomics, metabolomics and patient phenotyping to tailor treatments to underlying biological drivers of disease. Forte’s development programs have attracted collaborations with academic institutions and contract research organizations to accelerate clinical testing and formulation optimization.
Founded in 2017 and headquartered in San Diego, California, Forte Biosciences serves a global patient population through clinical sites in North America and Europe. The company’s manufacturing capabilities include a dedicated facility for live biotherapeutic production, enabling end-to-end control over strain propagation, formulation and quality assurance. Forte continues to expand its pipeline by exploring additional dermatologic indications such as seborrheic dermatitis and systemic inflammatory conditions linked to skin barrier dysfunction.
Forte’s leadership team brings together seasoned professionals in dermatology research, clinical development and regulatory affairs. The executive management features former senior leaders from established pharmaceutical and biotech firms, supported by a board of directors with extensive experience in commercial strategy and investment. This experienced team guides Forte’s strategic vision, clinical programs and partnerships as the company advances toward potential regulatory approvals and commercialization.
AI Generated. May Contain Errors.
Free FBRX Stock Alerts